• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克拉霉素及其他大环内酯类药物对肺炎衣原体(TWAR)标准菌株的体外活性。

The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR).

作者信息

Ridgway G L, Mumtaz G, Fenelon L

机构信息

Department of Clinical Microbiology, University College Hospital, London, UK.

出版信息

J Antimicrob Chemother. 1991 Feb;27 Suppl A:43-5. doi: 10.1093/jac/27.suppl_a.43.

DOI:10.1093/jac/27.suppl_a.43
PMID:1827101
Abstract

The activity of oxytetracycline and seven macrolide antibiotics was investigated against a prototype strain of Chlamydia pneumoniae in cell culture. Following incubation, inoculated cell monolayers were fixed in methanol and stained with a genus specific immunofluorescent monoclonal antibody before examination for inhibition of inclusion formation. The most active agent was clarithromycin (MIC 0.007 mg/l), followed by erythromycin (0.06 mg/l). Other macrolides were less active; josamycin and roxithromycin (0.25 mg/l), midecamycin acetate and azithromycin (0.5 mg/l) and spiramycin (4.0 mg/l). The MIC of oxytetracycline was 0.25 mg/l. Clinical evaluation of clarithromycin for C. pneumoniae lower respiratory infection is indicated.

摘要

在细胞培养中研究了土霉素和七种大环内酯类抗生素对肺炎衣原体原型菌株的活性。孵育后,将接种的细胞单层用甲醇固定,并用属特异性免疫荧光单克隆抗体染色,然后检查包涵体形成的抑制情况。活性最强的药物是克拉霉素(MIC 0.007毫克/升),其次是红霉素(0.06毫克/升)。其他大环内酯类药物活性较低;交沙霉素和罗红霉素(0.25毫克/升)、醋酸麦迪霉素和阿奇霉素(0.5毫克/升)以及螺旋霉素(4.0毫克/升)。土霉素的MIC为0.25毫克/升。表明应对克拉霉素用于肺炎衣原体下呼吸道感染进行临床评估。

相似文献

1
The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR).克拉霉素及其他大环内酯类药物对肺炎衣原体(TWAR)标准菌株的体外活性。
J Antimicrob Chemother. 1991 Feb;27 Suppl A:43-5. doi: 10.1093/jac/27.suppl_a.43.
2
The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.一些14元、15元和16元大环内酯类药物对葡萄球菌属、军团菌属、支原体属和溶脲脲原体的体外活性。
Drugs Exp Clin Res. 1991;17(2):91-9.
3
In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).肺炎衣原体(衣原体属TWAR株)的体外药敏试验
Antimicrob Agents Chemother. 1989 Sep;33(9):1634-5. doi: 10.1128/AAC.33.9.1634.
4
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.阿奇霉素、克拉霉素、左旋氧氟沙星及其他抗生素对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573.
5
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.16元环大环内酯类药物及泰利霉素对不同基因型的红霉素敏感及耐药化脓性链球菌和肺炎链球菌的活性。
J Antimicrob Chemother. 2007 Jun;59(6):1171-6. doi: 10.1093/jac/dkm089. Epub 2007 Apr 3.
6
Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.化脓性链球菌对阿奇霉素、克拉霉素、红霉素和罗红霉素的体外敏感性
J Med Microbiol. 1995 Nov;43(5):386-91. doi: 10.1099/00222615-43-5-386.
7
Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms.阿奇霉素、大环内酯类药物(红霉素、克拉霉素和螺旋霉素)及链阳菌素RP 59500对口腔微生物的体外活性比较
J Antimicrob Chemother. 1992 Jul;30(1):27-37. doi: 10.1093/jac/30.1.27.
8
In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.新型抗菌酮内酯类药物塞曲霉素对肺炎衣原体的体外活性
J Antimicrob Chemother. 2003 Sep;52(3):497-9. doi: 10.1093/jac/dkg371. Epub 2003 Aug 13.
9
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.阿奇霉素、克拉霉素、红霉素和四环素对13株肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1996 Jan;40(1):212-4. doi: 10.1128/AAC.40.1.212.
10
The in-vitro antibiotic susceptibility of Chlamydia pneumoniae.肺炎衣原体的体外抗生素敏感性
J Antimicrob Chemother. 1990 Dec;26(6):763-7. doi: 10.1093/jac/26.6.763.

引用本文的文献

1
In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.德国患者肺炎衣原体分离株的体外药敏性及抗生素联合用药的协同活性。
Antimicrob Agents Chemother. 1999 Jul;43(7):1808-10. doi: 10.1128/AAC.43.7.1808.
2
Chlamydia pneumoniae.肺炎衣原体
Thorax. 1993 Jan;48(1):1-4. doi: 10.1136/thx.48.1.1.
3
Clarithromycin clinical pharmacokinetics.克拉霉素的临床药代动力学。
Clin Pharmacokinet. 1993 Sep;25(3):189-204. doi: 10.2165/00003088-199325030-00003.
4
The new macrolides. Azithromycin and clarithromycin.新型大环内酯类药物。阿奇霉素和克拉霉素。
West J Med. 1994 Jan;160(1):31-7.
5
In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.斑点热群立克次体和伯氏考克斯氏体对克拉霉素的体外敏感性
Antimicrob Agents Chemother. 1993 Dec;37(12):2633-7. doi: 10.1128/AAC.37.12.2633.
6
In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.新型氮杂内酯类抗生素阿奇霉素对衣原体的体内外活性
Antimicrob Agents Chemother. 1994 Oct;38(10):2296-9. doi: 10.1128/AAC.38.10.2296.
7
Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.罗红霉素。其抗菌活性、药代动力学特性及治疗用途的最新进展。
Drugs. 1994 Aug;48(2):297-326. doi: 10.2165/00003495-199448020-00011.
8
Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.克拉霉素:抗菌活性、药代动力学特性及治疗潜力综述
Drugs. 1992 Jul;44(1):117-64. doi: 10.2165/00003495-199244010-00009.